Literature DB >> 28104247

Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.

Tuncay Gündüz1, Murat Kürtüncü1, Mefkure Eraksoy1.   

Abstract

Entities:  

Keywords:  Fingolimod withdrawal; Multiple sclerosis; Rebound disease activity

Mesh：

Substances：

Year:  2016        PMID： 28104247     DOI： 10.1016/j.msard.2016.11.003

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  6 in total

Review 1.  Neurological safety of fingolimod: An updated review.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Masafuchi Ryo; Wakoh Takahashi
Journal:  Clin Exp Neuroimmunol       Date:  2017-06-18

2.  Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.

Authors:  Cesar Alvarez-Gonzalez; Ashok Adams; Joela Mathews; Benjamin P Turner; Gavin Giovannoni; David Baker; Klaus Schmierer
Journal:  Ann Clin Transl Neurol       Date:  2017-05-17       Impact factor: 4.511

3.  Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.

Authors:  Kazunori Sato; Masaaki Niino; Atsushi Kawashima; Moemi Yamada; Yusei Miyazaki; Toshiyuki Fukazawa
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

4.  Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases.

Authors:  Stephan Schmidt; Thomas Schulten
Journal:  Ther Adv Neurol Disord       Date:  2019-05-06       Impact factor: 6.570

Review 5.  Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Authors:  Kerri A Schoedel; Carine Kolly; Anne Gardin; Srikanth Neelakantham; Kasra Shakeri-Nejad
Journal:  Psychopharmacology (Berl)       Date:  2021-11-13       Impact factor: 4.530

6.  Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.

Authors:  Assunta Bianco; Matteo Lucchini; Rocco Totaro; Roberta Fantozzi; Giovanna De Luca; Sonia Di Lemme; Giorgia Presicce; Luana Evangelista; Valeria Di Tommaso; Roberta Pastorino; Chiara De Fino; Valeria De Arcangelis; Diego Centonze; Massimiliano Mirabella
Journal:  Neurotherapeutics       Date:  2021-09-07       Impact factor: 7.620
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.